Home › NDC Lookup › RxCUI directory › RxCUI 2701422

0.8 ML olezarsen 100 MG/ML Auto-Injector — RxCUI 2701422

Name: 0.8 ML olezarsen 100 MG/ML Auto-Injector (RxCUI 2701422)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2701422 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2701422

Official name0.8 ML olezarsen 100 MG/ML Auto-Injector

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known asolezarsen 80 MG (equivalent to olezarsen sodium 84 MG) per 0.8 ML Auto-Injector; olezarsen 80 MG in 0.8 ML Auto-Injector

FDA products mapped2

Package NDCs mapped2

Reported Medicaid activity (SDUD)94 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

🕸️ Concept Web — How 0.8 ML olezarsen 100 MG/ML Auto-Injector Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 0.8 ML olezarsen 100 MG/ML Auto-Injector RxCUI 2701422 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Olezarsen 2701418 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Tryngolza 2701424 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Olezarsen Auto-Injector 2701421 SCDF
- Olezarsen Injectable Product 2701420 SCDG
- Olezarsen Auto-Injector [Tryngolza] 2701427 SBDF
- Tryngolza Injectable Product 2701426 SBDG
- Auto-Injector 1649570 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Olezarsen 100 MG/ML 2701419 SCDC
- 0.8 ML olezarsen 100 MG/ML Auto-Injector [Tryngolza] 2701428 SBD
- Olezarsen 100 MG/ML [Tryngolza] 2701425 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Olezarsen 100 MG/ML SCDC · 2701419
Olezarsen Auto-Injector SCDF · 2701421
Olezarsen Injectable Product SCDG · 2701420

Brand-Name Concepts

0.8 ML olezarsen 100 MG/ML Auto-Injector [Tryngolza] SBD · 2701428
Olezarsen 100 MG/ML [Tryngolza] SBDC · 2701425
Olezarsen Auto-Injector [Tryngolza] SBDF · 2701427
Tryngolza Injectable Product SBDG · 2701426
Tryngolza BN · 2701424

📦 FDA Products & Package NDCs

2 products · 2 package NDCs

2 package NDCs map to RxCUI 2701422 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
71860-0101-01	1 SYRINGE, GLASS in 1 CARTON (71860-101-01) / .8 mL in 1 SY...	TRYNGOLZA	Ionis Pharmaceuticals, Inc.	2024-12-19
71860-0102-01	1 SYRINGE, GLASS in 1 CARTON (71860-102-01) / .8 mL in 1 SY...	TRYNGOLZA	Ionis Pharmaceuticals, Inc.	2026-06-24

Observed labelers: Ionis Pharmaceuticals, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.